Neuropsychiatric lupus: a mosaic of clinical presentations

BMC Medicine

Yehuda Shoenfeld¹  Joab Chapman²  Gisele Zandman-Goddard²  Nancy Agmon-Levin²  Shaye Kivity² 

[1] The Zabludovicz Center for Autoimmune Diseases, The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel;Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 39040, Israel

关键词: Neuropsychiatric lupus;    Depression;    Cognitive impairment;    Auto-antibodies;    Anti-ribosomal-P;   

Others  :  1134631
DOI  :  10.1186/s12916-015-0269-8

 received in 2014-08-14, accepted in 2015-01-06,  发布年份 2015

【 摘 要 】

Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology, diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the future, thus allowing for better treatment strategies.

【 授权许可】

   
2015 Kivity et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
• [2]Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al.: Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001, 45:419-23.
• [3]Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME: The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010, 9:A277-87.
• [4]Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al.: Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002, 58:1214-20.
• [5]Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G: Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011, 41:1-11.
• [6]Hanly JG, Walsh NM, Sangalang V: Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992, 19:732-41.
• [7]Leah E: Bone: finding that osteoclasts repel osteoblast activity through Sema4D reveals novel target for bone-boosting therapies. Nat Rev Rheumatol. 2011, 7:681.
• [8]Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004, 34:501-37.
• [9]Zandman-Goddard G, Chapman J, Shoenfeld Y: Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007, 36:297-315.
• [10]Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA, Sanna G: Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol. 2014, 261:1706-14.
• [11]Briani C, Lucchetta M, Ghirardello A, Toffanin E, Zampieri S, Ruggero S, et al.: Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun. 2009, 32:79-84.
• [12]Carmona-Fernandes D, Santos MJ, Canhao H, Fonseca JE: Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Med. 2013, 11:98. BioMed Central Full Text
• [13]Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M: Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest. 1992, 89:1236-41.
• [14]Koscec M, Koren E, Wolfson-Reichlin M, Fugate RD, Trieu E, Targoff IN, et al.: Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol. 1997, 159:2033-41.
• [15]Stacey DW, Skelly S, Watson T, Elkon K, Weissbach H, Brot N: The inhibition of protein synthesis by IgG containing anti-ribosome P autoantibodies from systemic lupus erythematosus patients. Arch Biochem Biophys. 1988, 267:398-403.
• [16]Bravo-Zehnder M, Toledo EM, Segovia-Miranda F, Serrano FG, Benito MJ, Metz C, et al.: Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol. 2015, 67:204-14.
• [17]Diamond B, Volpe BT: A model for lupus brain disease. Immunol Rev. 2012, 248:56-67.
• [18]Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT: Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med. 2011, 269:36-44.
• [19]Hirohata S, Arinuma Y, Yanagida T, Yoshio T: Blood–brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther. 2014, 16:R77. BioMed Central Full Text
• [20]Faust TW, Chang EH, Kowal C, Berlin R, Gazaryan IG, Bertini E, et al.: Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci U S A. 2010, 107:18569-74.
• [21]Blank M, Shoenfeld Y: The story of the 16/6 idiotype and systemic lupus erythematosus. Isr Med Assoc J. 2008, 10:37-9.
• [22]Kivity S, Katzav A, Arango MT, Landau-Rabi M, Zafrir Y, Agmon-Levin N, et al.: 16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus. BMC Med. 2013, 11:90. BioMed Central Full Text
• [23]Meroni PL: Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun. 2008, 30:99-9103.
• [24]Tsuchiya H, Haga S, Takahashi Y, Kano T, Ishizaka Y, Mimori A: Identification of novel autoantibodies to GABA(B) receptors in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford). 2014, 53:1219-28.
• [25]Toubi E, Shoenfeld Y: Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev. 2007, 6:119-25.
• [26]Yoshio T, Okamoto H, Hirohata S, Minota S: IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum. 2013, 65:457-63.
• [27]Stock AD, Wen J, Putterman C: Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013, 4:484.
• [28]Rhiannon JJ: Systemic lupus erythematosus involving the nervous system: presentation, pathogenesis, and management. Clin Rev Allergy Immunol. 2008, 34:356-60.
• [29]Jeltsch-David H, Muller S: Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model. Autoimmun Rev. 2014, 13:963-73.
• [30]Gao H-X, Sanders E, Tieng AT, Putterman C: Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. J Neuroimmunol. 2010, 229:112-22.
• [31]Gulinello M, Putterman C: The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus. J Biomed Biotechnol. 2011, 2011:207504.
• [32]Sled JG, Spring S, van Eede M, Lerch JP, Ullal S, Sakic B: Time course and nature of brain atrophy in the MRL mouse model of central nervous system lupus. Arthritis Rheum. 2009, 60:1764-74.
• [33]Zardi EM, Taccone A, Marigliano B, Margiotta DPE, Afeltra A: Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun Rev. 2014, 13:831-9.
• [34]Williams S, Stafford P, Hoffman SA: Diagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarrays. BMC Immunol. 2014, 15:23. BioMed Central Full Text
• [35]Gonzalez LA, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS: Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus. 2009, 18:822-30.
• [36]Zirkzee EJM, Huizinga TWJ, Bollen ELEM, van Buchem MA, Middelkoop HAM, van der Wee NJA, et al.: Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014, 23:31-8.
• [37]Hanly JG, Urowitz MB, O’Keeffe AG, Gordon C, Bae S-C, Sanchez-Guerrero J, et al.: Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013, 65:2887-97.
• [38]Mitsikostas DD, Sfikakis PP, Goadsby PJ: A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004, 127:1200-9.
• [39]Gonzalez-Duarte A, Cantu-Brito CG, Ruano-Calderon L, Garcia-Ramos G: Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol. 2008, 59:320-3.
• [40]Andrade RM, Alarcon GS, Gonzalez LA, Fernandez M, Apte M, Vila LM, et al.: Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis. 2008, 67:829-34.
• [41]Hanly JG, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guerrero J, et al.: Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012, 71:1502-9.
• [42]Timlin H, Petri M: Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus. 2013, 22:1251-8.
• [43]Petri M, Orbai A-M, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al.: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64:2677-86.
• [44]Matsuura E, Hughes GRV, Khamashta MA: Oxidation of LDL and its clinical implication. Autoimmun Rev. 2008, 7:558-66.
• [45]Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL: Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005, 95:1441-7.
• [46]Magro Checa C, Cohen D, Bollen ELEM, van Buchem MA, Huizinga TWJ, Steup-Beekman GM: Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract Res Clin Rheumatol. 2013, 27:405-24.
• [47]Uthman I, Noureldine MH, Berjawi A, Skaf M, Haydar AA, Merashli M, et al.: Hughes syndrome and multiple sclerosis. Lupus 2014, 24:115-21.
• [48]Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ: Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000, 59:120-4.
• [49]Baizabal-Carvallo JF, Bonnet C, Jankovic J: Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm. 2013, 120:1579-89.
• [50]Joseph FG, Lammie GA, Scolding NJ: CNS lupus: a study of 41 patients. Neurology. 2007, 69:644-54.
• [51]Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED: A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008, 59:206-13.
• [52]Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al.: Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore). 1997, 76:203-12.
• [53]Dale RC, Yin K, Ding A, Merheb V, Varadkhar S, McKay D, et al.: Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol. 2011, 53:522-8.
• [54]Galanaud D, Dormont D, Marsault C, Wechsler B, Piette JC: Brain MRI in patients with past lupus-associated chorea. Stroke. 2000, 31:3079-83.
• [55]Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A: The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001, 57:496-500.
• [56]Hanly JG, Fisk JD, Sherwood G, Eastwood B: Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol. 1994, 21:1825-31.
• [57]van Exel E, Jacobs J, Korswagen LA, Voskuyl AE, Stek M, Dekker J, et al.: Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus. 2013, 22:1462-9.
• [58]Bachen EA, Chesney MA, Criswell LA: Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009, 61:822-9.
• [59]Huang X, Magder LS, Petri M: Predictors of incident depression in systemic lupus erythematosus. J Rheumatol. 2014, 41:1823-33.
• [60]Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al.: Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2505-14. and reference
• [61]Maneeton B, Maneeton N, Louthrenoo W: Prevalence and predictors of depression in patients with systemic lupus erythematosus: a cross-sectional study. Neuropsychiatr Dis Treat. 2013, 9:799-804.
• [62]Appenzeller S, Cendes F, Costallat LT: Acute psychosis in systemic lupus erythematosus. Rheumatol Int. 2008, 28:237-43.
• [63]Pego-Reigosa JM, Isenberg DA: Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford). 2008, 47:1498-502.
• [64]Sirois F: Steroid psychosis: a review. Gen Hosp Psychiatry. 2003, 25:27-33.
• [65]Kampylafka EI, Alexopoulos H, Kosmidis ML, Panagiotakos DB, Vlachoyiannopoulos PG, Dalakas MC, et al.: Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One. 2013, 8:e55843.
• [66]Shoenfeld N, Agmon-Levin N, Flitman-Katzevman I, Paran D, Katz BS, Kivity S, et al.: The sense of smell in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1484-7.
• [67]Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y: Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun. 2008, 31:393-8.
• [68]Kivity S, Tsarfaty G, Agmon-Levin N, Blank M, Manor D, Konen E, et al.: Abnormal olfactory function demonstrated by manganese-enhanced MRI in mice with experimental neuropsychiatric lupus. Ann N Y Acad Sci. 2010, 1193:70-7.
• [69]Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR: Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011, 41:203-11.
• [70]Oomatia A, Fang H, Petri M, Birnbaum J: Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol. 2014, 66:1000-9.
• [71]Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al.: International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014, 73:17-23.
• [72]Galeazzi M, Annunziata P, Sebastiani GD, Bellisai F, Campanella V, Ferrara GB, et al.: Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations: European Concerted Action on the Immunogenetics of SLE. J Rheumatol. 2000, 27:135-41.
• [73]McLean BN, Miller D, Thompson EJ: Oligoclonal banding of IgG in CSF, blood–brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet’s disease involving the nervous system. J Neurol Neurosurg Psychiatry. 1995, 58:548-54.
• [74]Fragoso-Loyo H, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J: Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford). 2013, 52:2218-22.
• [75]Lu XY, Zhu CQ, Qian J, Chen XX, Ye S, Gu YY: Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus. 2010, 19:689-95.
• [76]Kozora E, Ellison MC, West S: Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum. 2004, 51:810-8.
• [77]Jeltsch-David H, Muller S: Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014, 10:579-96.
• [78]Brunner HI, Klein-Gitelman MS, Zelko F, Beebe DW, Foell D, Lee J, et al.: Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children. Lupus Sci Med. 2014, 1:e000038.
• [79]Toledano P, Sarbu N, Espinosa G, Bargallo N, Cervera R: Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev. 2013, 12:1166-70.
• [80]Jeong HW, Her M, Bae JS, Kim SK, Lee SW, Kim HK, et al. Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions. Rheumatol Int. 2014. [Ahead of print.]
• [81]Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, et al.: Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis. 2000, 59:377-85.
• [82]Appenzeller S, Costallat LTL, Li LM, Cendes F: Magnetic resonance spectroscopy in the evaluation of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006, 55:807-11.
• [83]Gal Y, Twig G, Mozes O, Greenberg G, Hoffmann C, Shoenfeld Y: Central nervous system involvement in systemic lupus erythematosus: an imaging challenge. Isr Med Assoc J. 2013, 15:382-6.
• [84]Peterson PL, Axford JS, Isenberg D: Imaging in CNS lupus. Best Pract Res Clin Rheumatol. 2005, 19:727-39.
• [85]Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al.: Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005, 64:620-5.
• [86]Stojanovich L, Stojanovich R, Kostich V, Dzjolich E: Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003, 12:3-7.
• [87]Tomietto P, D’Agostini S, Annese V, De Vita S, Ferraccioli G: Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol. 2007, 34:588-91.
• [88]Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO, Rua-Figueroa I, Fernandez-Nebro A, et al.: Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014, 44:175-85.
• [89]Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:721-31.
• [90]Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012, 71:1833-8.
• [91]Bartolucci P, Brechignac S, Cohen P, Le Guern V, Guillevin L: Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007, 16:817-22.
• [92]Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y: Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012, 42:247-55.
• [93]Bertsias GK, Boumpas DT: Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010, 6:358-67.
• [94]Ruiz-Irastorza G, Hunt BJ, Khamashta MA: A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007, 57:1487-95.